Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Quality of life and mental health in hemodialysis patients: a challenge for multiprofessional practices.

Schmidt DB.

J Bras Nefrol. 2019 Jan-Mar;41(1):10-11. doi: 10.1590/2175-8239-JBN-2018-0227. Epub 2019 Jan 21. English, Portuguese. No abstract available.

2.

Quality of life and mental health in hemodialysis patients: a challenge for multiprofessional practices.

Schmidt DB.

J Bras Nefrol. 2019 Jan 21. pii: S0101-28002019005003102. doi: 10.1590/2175-8239-JBN-2018-0227. [Epub ahead of print] English, Portuguese. No abstract available.

3.

Hospitalizations for diabetes mellitus and the Family Health Strategy, Paraná, Brazil, 2000-2012.

Arruda GO, Schmidt DB, Marcon SS.

Cien Saude Colet. 2018 Feb;23(2):543-552. doi: 10.1590/1413-81232018232.23092015. Portuguese, English.

4.

Quality of life in hemodialysis patients and the relationship with mortality, hospitalizations and poor treatment adherence.

Oliveira AP, Schmidt DB, Amatneeks TM, Santos JC, Cavallet LH, Michel RB.

J Bras Nefrol. 2016 Dec;38(4):411-420. doi: 10.5935/0101-2800.20160066. Portuguese, English.

5.

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy.

Castillo SM, Schmidt DB, White S, Shukralla A.

Cochrane Database Syst Rev. 2016 Nov 15;11:CD002028. Review.

6.

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ, Slack RJ, Sarau HM, Palovich MR, Lainé DI, Hay DW, Rumsey WL.

J Pharmacol Exp Ther. 2013 May;345(2):260-70. doi: 10.1124/jpet.112.202051. Epub 2013 Feb 22.

PMID:
23435542
7.

Tyrosine urea muscarinic acetylcholine receptor antagonists: achiral quaternary ammonium groups.

Jin Q, Davis RS, Bullion AM, Jin J, Wang Y, Widdowson KL, Palovich MR, Foley JJ, Schmidt DB, Buckley PT, Webb EF, Salmon M, Belmonte KE, Sarau HM, Busch-Petersen J.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7087-91. doi: 10.1016/j.bmcl.2012.09.085. Epub 2012 Oct 2.

PMID:
23099092
8.

Is "processed" a four-letter word? The role of processed foods in achieving dietary guidelines and nutrient recommendations.

Dwyer JT, Fulgoni VL 3rd, Clemens RA, Schmidt DB, Freedman MR.

Adv Nutr. 2012 Jul 1;3(4):536-48. doi: 10.3945/an.111.000901.

9.

Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Yan H, Xie H, Davis RS, Dufour J, Widdowson KL, Palovich MR, Wan Z, Foley JJ, Schmidt DB, Hunsberger GE, Burman M, Bacon AM, Webb EF, Luttmann MA, Salmon M, Sarau HM, Umbrecht ST, Landis PS, Peck BJ, Busch-Petersen J.

Bioorg Med Chem Lett. 2012 May 1;22(9):3366-9. doi: 10.1016/j.bmcl.2012.02.015. Epub 2012 Feb 15.

PMID:
22460029
10.

Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD.

Wan Z, Laine DI, Yan H, Zhu C, Widdowson KL, Buckley PT, Burman M, Foley JJ, Sarau HM, Schmidt DB, Webb EF, Belmonte KE, Palovich M.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. doi: 10.1016/j.bmcl.2009.07.006. Epub 2009 Jul 8.

PMID:
19616944
11.

Exploring global consumer attitudes toward nutrition information on food labels.

Wills JM, Schmidt DB, Pillo-Blocka F, Cairns G.

Nutr Rev. 2009 May;67 Suppl 1:S102-6. doi: 10.1111/j.1753-4887.2009.00170.x. Review.

PMID:
19453661
12.

Optimized procedures for producing biologically active chemokines.

Lu Q, Burns MC, McDevitt PJ, Graham TL, Sukman AJ, Fornwald JA, Tang X, Gallagher KT, Hunsberger GE, Foley JJ, Schmidt DB, Kerrigan JJ, Lewis TS, Ames RS, Johanson KO.

Protein Expr Purif. 2009 Jun;65(2):251-60.

PMID:
19297698
13.

Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.

Wang Y, Busch-Petersen J, Wang F, Kiesow TJ, Graybill TL, Jin J, Yang Z, Foley JJ, Hunsberger GE, Schmidt DB, Sarau HM, Capper-Spudich EA, Wu Z, Fisher LS, McQueney MS, Rivero RA, Widdowson KL.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):114-8. doi: 10.1016/j.bmcl.2008.11.008. Epub 2008 Nov 6.

PMID:
19014886
14.

3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.

Wang Y, Busch-Petersen J, Wang F, Ma L, Fu W, Kerns JK, Jin J, Palovich MR, Shen JK, Burman M, Foley JJ, Schmidt DB, Hunsberger GE, Sarau HM, Widdowson KL.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3864-7. Epub 2007 May 10.

PMID:
17524641
15.

Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.

McCleland BW, Davis RS, Palovich MR, Widdowson KL, Werner ML, Burman M, Foley JJ, Schmidt DB, Sarau HM, Rogers M, Salyers KL, Gorycki PD, Roethke TJ, Stelman GJ, Azzarano LM, Ward KW, Busch-Petersen J.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. Epub 2006 Dec 23.

PMID:
17236763
16.

N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.

Nie H, Widdowson KL, Palovich MR, Fu W, Elliott JD, Bryan DL, Burman M, Schmidt DB, Foley JJ, Sarau HM, Busch-Petersen J.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5513-6. Epub 2006 Aug 24.

PMID:
16934456
17.

The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt DB, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo' G, Camarda V, Aiyar NV, Douglas SA.

Br J Pharmacol. 2006 May;148(2):173-90.

18.

Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.

Jin J, Dhanak D, Knight SD, Widdowson K, Aiyar N, Naselsky D, Sarau HM, Foley JJ, Schmidt DB, Bennett CD, Wang B, Warren GL, Moore ML, Keenan RM, Rivero RA, Douglas SA.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3229-32.

PMID:
15936190
19.

Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, Ohlstein EH, Gleason JG, Sarau HM, Foley JJ, Buckley PT, Schmidt DB, Wixted WE, Widdowson K, Riley G, Jin J, Gallagher TF, Schmidt SJ, Ridgers L, Christmann LT, Keenan RM, Knight SD, Dhanak D.

Br J Pharmacol. 2005 Jul;145(5):620-35.

20.

A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma.

Pillai SG, Cousens DJ, Barnes AA, Buckley PT, Chiano MN, Hosking LK, Cameron LA, Fling ME, Foley JJ, Green A, Sarau HM, Schmidt DB, Sprankle CS, Blumenthal MN, Vestbo J, Kennedy-Wilson K, Wixted WE, Wagner MJ, Anderson WH, Ignar DM; Investigators of the GAIN Network.

Pharmacogenetics. 2004 Sep;14(9):627-33.

PMID:
15475736
21.

Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease.

Hardaker EL, Bacon AM, Carlson K, Roshak AK, Foley JJ, Schmidt DB, Buckley PT, Comegys M, Panettieri RA Jr, Sarau HM, Belmonte KE.

FASEB J. 2004 Jan;18(1):191-3. Epub 2003 Nov 3.

PMID:
14597565
22.

A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit.

Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, Hagen TR, Kajikawa O, Marshall LA, Hay DW, Sarau HM.

J Immunol. 2002 Dec 1;169(11):6435-44.

23.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

Hay DW, Giardina GA, Griswold DE, Underwood DC, Kotzer CJ, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Martin LD, Kilian D, Legos JJ, Barone FC, Luttmann MA, Grugni M, Raveglia LF, Sarau HM.

J Pharmacol Exp Ther. 2002 Jan;300(1):314-23.

PMID:
11752131
24.

Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.

Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, Buckley PT, Elshourbagy NA, Brawner ME, Luttmann MA, Giardina GA, Hay DW.

Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50.

PMID:
11226387
25.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 2000 Oct;295(1):373-81.

PMID:
10992004
26.

Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration.

White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan G, Fornwald JA, Dhanak D, Christmann LT, Darcy MG, Widdowson KL, Foley JJ, Schmidt DB, Sarau HM.

J Biol Chem. 2000 Nov 24;275(47):36626-31.

27.

Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.

Sarau HM, Mooney JL, Schmidt DB, Foley JJ, Buckley PT, Giardina GA, Wang DY, Lee JA, Hay DW.

Mol Pharmacol. 2000 Sep;58(3):552-9.

PMID:
10953048
28.

Oxcarbazepine add-on for drug-resistant partial epilepsy.

Castillo S, Schmidt DB, White S.

Cochrane Database Syst Rev. 2000;(3):CD002028. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 15;11:CD002028.

PMID:
10908522
29.

Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor.

Elshourbagy NA, Ames RS, Fitzgerald LR, Foley JJ, Chambers JK, Szekeres PG, Evans NA, Schmidt DB, Buckley PT, Dytko GM, Murdock PR, Milligan G, Groarke DA, Tan KB, Shabon U, Nuthulaganti P, Wang DY, Wilson S, Bergsma DJ, Sarau HM.

J Biol Chem. 2000 Aug 25;275(34):25965-71.

30.

Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke.

Wang X, Li X, Schmidt DB, Foley JJ, Barone FC, Ames RS, Sarau HM.

Mol Pharmacol. 2000 Jun;57(6):1190-8.

PMID:
10825390
31.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

Sarau HM, Foley JJ, Schmidt DB, Martin LD, Webb EF, Tzimas MN, Breton JJ, Chabot-Fletcher M, Underwood DC, Hay DW, Kingsbury WD, Chambers PA, Pendrak I, Jakas DR, Sathe GM, Van Horn S, Daines RA, Griswold DE.

Prostaglandins Leukot Essent Fatty Acids. 1999 Jul;61(1):55-64.

PMID:
10477044
32.

Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.

Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, Schmidt DB, Muccitelli RM, Jenkins O, Murdock PR, Herrity NC, Halsey W, Sathe G, Muir AI, Nuthulaganti P, Dytko GM, Buckley PT, Wilson S, Bergsma DJ, Hay DW.

Mol Pharmacol. 1999 Sep;56(3):657-63.

PMID:
10462554
33.

Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.

Giardina GA, Artico M, Cavagnera S, Cerri A, Consolandi E, Gagliardi S, Graziani D, Grugni M, Hay DW, Luttmann MA, Mena R, Raveglia LF, Rigolio R, Sarau HM, Schmidt DB, Zanoni G, Farina C.

Farmaco. 1999 Jun 30;54(6):364-74.

PMID:
10443017
34.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).

Giardina GA, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S, Foley JJ, Vecchietti V, Hay DW.

J Med Chem. 1999 Mar 25;42(6):1053-65.

PMID:
10090788
35.

Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils.

White JR, Imburgia C, Dul E, Appelbaum E, O'Donnell K, O'Shannessy DJ, Brawner M, Fornwald J, Adamou J, Elshourbagy NA, Kaiser K, Foley JJ, Schmidt DB, Johanson K, Macphee C, Moores K, McNulty D, Scott GF, Schleimer RP, Sarau HM.

J Leukoc Biol. 1997 Nov;62(5):667-75.

PMID:
9365122
36.

Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.

Sarau HM, Rush JA, Foley JJ, Brawner ME, Schmidt DB, White JR, Barnette MS.

J Pharmacol Exp Ther. 1997 Oct;283(1):411-8.

PMID:
9336350
37.

Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B.

Berkhout TA, Sarau HM, Moores K, White JR, Elshourbagy N, Appelbaum E, Reape RJ, Brawner M, Makwana J, Foley JJ, Schmidt DB, Imburgia C, McNulty D, Matthews J, O'Donnell K, O'Shannessy D, Scott M, Groot PH, Macphee C.

J Biol Chem. 1997 Jun 27;272(26):16404-13.

38.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.

Giardina GA, Sarau HM, Farina C, Medhurst AD, Grugni M, Raveglia LF, Schmidt DB, Rigolio R, Luttmann M, Vecchietti V, Hay DW.

J Med Chem. 1997 Jun 6;40(12):1794-807.

PMID:
9191956
39.

Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.

Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 1997 Jun;281(3):1303-11.

PMID:
9190866
40.

(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.

Daines RA, Chambers PA, Foley JJ, Griswold DE, Kingsbury WD, Martin LD, Schmidt DB, Sham KK, Sarau HM.

J Med Chem. 1996 Sep 13;39(19):3837-41.

PMID:
8809171
41.

2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.

Giardina GA, Sarau HM, Farina C, Medhurst AD, Grugni M, Foley JJ, Raveglia LF, Schmidt DB, Rigolio R, Vassallo M, Vecchietti V, Hay DW.

J Med Chem. 1996 Jun 7;39(12):2281-4. No abstract available.

PMID:
8691422
42.

Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke.

Barone FC, Hillegass LM, Tzimas MN, Schmidt DB, Foley JJ, White RF, Price WJ, Feuerstein GZ, Clark RK, Griswold DE, et al.

Mol Chem Neuropathol. 1995 Jan;24(1):13-30.

PMID:
7755844
43.

SB 209247, a high affinity LTB4 receptor antagonist demonstrating potent antiinflammatory activity.

Sarau HM, Foley JJ, Schmidt DB, Tzimas MN, Martin LD, Daines RA, Chambers PA, Kingsbury WD, Griswold DE.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:275-7. No abstract available.

PMID:
7732852
44.

Effects of scalaradial, a novel inhibitor of 14 kDa phospholipase A2, on human neutrophil function.

Barnette MS, Rush J, Marshall LA, Foley JJ, Schmidt DB, Sarau HM.

Biochem Pharmacol. 1994 Apr 29;47(9):1661-7.

PMID:
8185681
45.

Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist Leucettamine A and related analogues.

Boehm JC, Gleason JG, Pendrak I, Sarau HM, Schmidt DB, Foley JJ, Kingsbury WD.

J Med Chem. 1993 Oct 29;36(22):3333-40.

PMID:
8230123
46.

Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.

Daines RA, Chambers PA, Pendrak I, Jakas DR, Sarau HM, Foley JJ, Schmidt DB, Kingsbury WD.

J Med Chem. 1993 Oct 29;36(22):3321-32.

PMID:
8230122
47.

Synthesis of structural analogs of leukotriene B4 and their receptor binding activity.

Kingsbury WD, Pendrak I, Leber JD, Boehm JC, Mallet B, Sarau HM, Foley JJ, Schmidt DB, Daines RA.

J Med Chem. 1993 Oct 29;36(22):3308-20.

PMID:
8230121
48.

(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.

Daines RA, Chambers PA, Pendrak I, Jakas DR, Sarau HM, Foley JJ, Schmidt DB, Griswold DE, Martin LD, Tzimas MN, et al.

J Med Chem. 1993 Sep 3;36(18):2703-5. No abstract available. Erratum in: J Med Chem 1993 Dec 10;36(25):4130.

PMID:
8410983
49.

Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia.

Barone FC, Schmidt DB, Hillegass LM, Price WJ, White RF, Feuerstein GZ, Clark RK, Lee EV, Griswold DE, Sarau HM.

Stroke. 1992 Sep;23(9):1337-47; discussion 1347-8.

PMID:
1381529

Supplemental Content

Loading ...
Support Center